Hypera S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
October 27, 2022 at 07:07 pm EDT
Share
Hypera S.A. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net income was BRL 465.37 million compared to BRL 201.7 million a year ago. Basic earnings per share from continuing operations was BRL 0.74208 compared to BRL 0.73511 a year ago. Basic earnings per share was BRL 0.73 compared to BRL 0.32 a year ago.
For the nine months, net income was BRL 1,268.82 million compared to BRL 977.81 million a year ago. Basic earnings per share from continuing operations was BRL 2.01688 compared to BRL 1.98031 a year ago. Basic earnings per share was BRL 2.01 compared to BRL 1.55 a year ago.
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.
HYPERA S.A. 
